Updated
The most significant concentration Korsana Biosciences discloses is lead product candidate for treatment resistant depression, classified MEDIUM by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Korsana Biosciences’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
“10-K Item 1A: 'Our business depends heavily on the successful development, clinical testing, regulatory approvals and commercialization of our lead product candidate for treatment resistant depression'”
“10-K Item 1A: 'Akebia may not be successful in developing and commercializing any therapies through its praliciguat out-license with the Company.'”
“10-K Item 1A: 'There is uncertainty as to any liquidity or monetizable value of our equity interest in Tisento, a privately-held company'”
Korsana's concentration risk is a pre-commercial, pipeline-style profile. The business depends heavily on the successful development, clinical testing, regulatory approvals and commercialization of its lead product candidate for treatment resistant depression. That is a structural, single-asset exposure: the company's value is tied to one program's clinical and regulatory outcome rather than to a diversified revenue base. Two secondary exposures are counterparty-driven. Akebia may not be successful in developing and commercializing any therapies through its praliciguat out-license with the company, which makes any value from that asset dependent on a partner's execution rather than Korsana's own. Separately, the filing flags uncertainty about any liquidity or monetizable value of the company's equity interest in Tisento, a privately-held company. This is a small, idiosyncratic dependency that is hard to realize in cash. Netted together, the lead candidate is the structural driver that could move the verdict, while the Akebia out-license and the Tisento stake are partner and illiquidity dependencies that add optionality but are not reliable sources of near-term value. All are disclosed in the 10-K.
For the engine’s reasoning on KRSA’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | 2 | 0 | 0 | 2 |
| ABUS | Arbutus Biopharma Corporation | 1 | 1 | 0 | 2 |
| ABSI | Absci Corporation | 1 | 0 | 0 | 1 |
| KRSA● | Korsana Biosciences, Inc. | 0 | 2 | 1 | 3 |
| ABCL | AbCellera Biologics Inc. | 0 | 0 | 0 | 0 |
| ACHV | Achieve Life Sciences, Inc. | 0 | 0 | 0 | 0 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.